Groups and Subgroups in Autism Spectrum Disorder (ASD) Considering an Advanced Integrative Model (AIM).

IF 3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Personalized Medicine Pub Date : 2024-09-27 DOI:10.3390/jpm14101031

Andrés Ciolino, María Luján Ferreira, Nicolás Loyacono

{"title":"Groups and Subgroups in Autism Spectrum Disorder (ASD) Considering an Advanced Integrative Model (AIM).","authors":"Andrés Ciolino, María Luján Ferreira, Nicolás Loyacono","doi":"10.3390/jpm14101031","DOIUrl":null,"url":null,"abstract":"Background: Autism spectrum disorder (ASD) is related to social communication difficulties, repetitive behaviors, and highly restricted interests beginning early in life. Currently, ASD is more diagnosed than in the past, and new models are needed. The Advanced Integrative Model (AIM) is a new model in which genes and concomitant medical problems to diagnosis (CMPD) and the impact of their rigorous and adequate treatment are considered.Methods: The role of a dynamic encephalopathy from which the individual response, susceptibilities in the brain and outside the brain, gut barrier and brain-blood-barrier permeabilities, and the plastic nature of the brain is proposed as a tool for diagnosis. The concomitant medical problems (CMP) are those at and outside the brain. The individual response to treatments of CMP is analyzed.Results: The AIM allows for classification into 3 main groups and 24 subgroups.Conclusions: The groups and subgroups in ASD are obtained taking into account CMPD treatments and individual response.","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"14 10","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508306/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm14101031","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Autism spectrum disorder (ASD) is related to social communication difficulties, repetitive behaviors, and highly restricted interests beginning early in life. Currently, ASD is more diagnosed than in the past, and new models are needed. The Advanced Integrative Model (AIM) is a new model in which genes and concomitant medical problems to diagnosis (CMPD) and the impact of their rigorous and adequate treatment are considered.

Methods: The role of a dynamic encephalopathy from which the individual response, susceptibilities in the brain and outside the brain, gut barrier and brain-blood-barrier permeabilities, and the plastic nature of the brain is proposed as a tool for diagnosis. The concomitant medical problems (CMP) are those at and outside the brain. The individual response to treatments of CMP is analyzed.

Results: The AIM allows for classification into 3 main groups and 24 subgroups.

Conclusions: The groups and subgroups in ASD are obtained taking into account CMPD treatments and individual response.

查看原文本刊更多论文

自闭症谱系障碍 (ASD) 中的群体和亚群体，考虑高级整合模式 (AIM)。

背景：自闭症谱系障碍（ASD）与社交沟通障碍、重复行为和高度受限的兴趣有关，从生命早期就开始出现。目前，自闭症的诊断率高于以往，因此需要新的模式。高级综合模型（AIM）是一种新的模型，其中考虑了基因和伴随的医学问题对诊断（CMPD）的影响，以及对其进行严格和充分治疗的影响：方法：提出了动态脑病的作用，并将其中的个体反应、大脑内外的易感性、肠道屏障和脑-血屏障的通透性以及大脑的可塑性作为诊断工具。伴随性疾病（CMP）是指脑部和脑部以外的疾病。结果：结果：AIM 可分为 3 个主要组别和 24 个亚组：结论：考虑到 CMPD 治疗和个体反应，可以得出 ASD 的组别和亚组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Personalized Medicine Medicine-Medicine (miscellaneous)

CiteScore

4.10

自引率

0.00%

发文量

1878

审稿时长

11 weeks

期刊介绍： Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.